Embodiment 421

The method, composition, molecular complex, dosage form, or product, of any preceding embodiment, wherein zoledronic acid or neridronic acid decreases CTX serum levels by at least about 95%.

Embodiment 422

The method, composition, molecular complex, dosage form, or product, of any preceding embodiment, wherein zoledronic acid or neridronic acid decreases CTX serum levels by at least about 99%.

Embodiment 423

The method, composition, molecular complex, dosage form, or product, of any preceding embodiment, wherein zoledronic acid or neridronic acid decreases CTX serum levels by at least about 100%.

Embodiment 424

The method, dosage form, or product, of any preceding embodiment, wherein the zoledronic acid is orally administered in a manner that results in a 24 hour sustained plasma level factor that is at least 1.5 times that of 4 mg of zoledronic acid administered intravenously.

Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood in all instances as indicating both the exact values as shown and as being modified by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

The terms "a," "an," "the" and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of any claim. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

Groupings of alternative elements or embodiments disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

Certain embodiments are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, the claims include all modifications and equivalents of the subject matter recited in the claims as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is contemplated unless otherwise indicated herein or otherwise clearly contradicted by context.

In closing, it is to be understood that the embodiments disclosed herein are illustrative of the principles of the claims. Other modifications that may be employed are within the scope of the claims. Thus, by way of example, but not of limitation, alternative embodiments may be utilized in accordance with the teachings herein. Accordingly, the claims are not limited to embodiments precisely as shown and described.

What is claimed is:

1. A method of treating pain associated with complex regional pain syndrome (CRPS) comprising selecting a human being having CRPS triggered by bone fracture and administering neridronic acid or a pharmaceutically acceptable salt thereof to the human being, wherein the treatment is effective in reducing pain.

2. The method of claim **1**, wherein the CRPS is CRPS type I.

3. The method of claim **1**, wherein the neridronic acid is in a salt form.

4. The method of claim **1**, wherein the neridronic acid is administered intravenously.

5. The method of claim **1**, wherein the neridronic acid is administered orally.

6. The method of claim **5**, wherein a total of about 50 mg to about 500 mg of the neridronic acid is administered daily.

7. The method of claim **5**, wherein a total of about 100 mg to about 500 mg of the neridronic acid is administered daily.

8. The method of claim **5**, wherein a total of about 150 mg to about 300 mg of the neridronic acid is administered daily.

9. The method of claim **1**, wherein the neridronic acid is administered parenterally.

10. The method of claim **9**, wherein a total of about 5 mg to about 500 mg of the neridronic acid is administered within one month.

11. The method of claim **9**, wherein a total of about 5 mg to about 200 mg of the neridronic acid is administered within one month.

12. The method of claim **9**, wherein each dose contains about 10 mg to about 150 mg of the neridronic acid.

13. The method of claim **9**, wherein a total of about 100 mg to about 300 mg of the neridronic acid is administered within one month.

14. The method of claim **1**, wherein a total of about 100 mg to about 600 mg of the neridronic acid is administered.

15. The method of claim **1**, wherein a total of about 100 mg to about 300 mg of the neridronic acid is administered.

16. The method of claim **4**, wherein each dose contains about 10 mg to about 150 mg of the neridronic acid.

17. The method of claim **4**, wherein each dose contains about 100 mg of the neridronic acid.

18. The method of claim **17**, wherein the neridronic acid is administered at least four times.